IMMX
Immix Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.22
+3.01%Sep 29, 2026, 11:05 UTC
Immix Biopharma priced an underwritten registered offering of 11,363,637 common shares at $11.00 per share, expecting gross proceeds of $125 million and a close on or about September 30, 2026.
Sep 29, 2026, 11:00 UTC
Immix Biopharma announced an interim update showing an 89% complete response rate across all NEXICART-2 patients, with MRD-negativity indicating a potential to reach up to 98% complete response rate in relapsed/refractory AL amyloidosis.
Aug 25, 2026, 07:47 UTC
Immix Biopharma's stock reached a new 52-week high of $13.80 during mid-day trading on Tuesday, with the last trade at $13.61 and volume of 1,414,936 shares.
Source:Jul 21, 2026, 17:51 UTC
The Portnoy Law Firm initiated an investigation into Immix Biopharma for possible securities fraud and may file a class action on behalf of investors.